Lg. Luciani et al., Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: An investigational approach, UROLOGY, 58(3), 2001, pp. 376-379
Objectives. To assess the risk of continued intravesical therapy and delaye
d cystectomy in the management of superficial bladder cancer refractory to
bacillus Calmette-Guerin (BCG) therapy.
Methods. We retrospectively reviewed the medical records of 24 patients who
underwent an experimental intravesical treatment with BCG plus interferon
alpha-2b or valrubicin for transitional cell carcinoma of the bladder. All
patients had Stage Tis and/or T1 transitional cell carcinoma and had failed
multiple prior courses of intravesical therapy, including at least one cou
rse of BCG.
Results. Patients were followed up for a median of 28.5 months (range 6 to
48). One patient died of unrelated disease. All other patients were alive a
t last follow-up. Fourteen patients with preserved bladder were continuing
cystoscopic surveillance: four had no recurrence, five had recurrence limit
ed to the mucosa (Ta or Tis) and became free of disease after an additional
course of intravesical therapy, and five had recurrent Ta or Tis or positi
ve cytologic findings. The remaining 9 patients underwent radical cystectom
y. All pathologic specimens showed no evidence of progression to muscle-inv
asive disease. Tis of the resected ureters in 6 and involvement of the pros
tate in 4 of the 9 patients (three in the urethral ducts and glands and one
in the prostatic stroma) were noted.
Conclusions. A select group of patients with BCG-refractory transitional ce
ll carcinoma and a poor surgical risk for cystectomy may benefit from conti
nued intravesical therapy without a significant risk of progression. Howeve
r, a cautious approach to this treatment modality is recommended, and very
close follow-up is necessary to detect bladder recurrences and involvement
of the upper tract and prostatic urethra. UROLOGY 58: 376-379, 2001. (C) 20
01, Elsevier Science Inc.